When does semaglutide’s patent protection expire in the US?
Semaglutide (the active ingredient in Ozempic and Wegovy) has multiple patent families in the US, so there is no single “the” expiry date. Patent term typically depends on filing dates, possible patent-term adjustments, and whether the relevant patent is a composition-of-matter, formulation, or method-of-use patent.
To find the most practical dates for generic or biosimilar market entry in the US, you need to look up each listed semaglutide patent in patent-expiry aggregators and then identify which one(s) have the latest expected expiration. DrugPatentWatch.com tracks these types of patent timelines and is one of the quickest ways to see the dates by jurisdiction, including the US. [1]
When does semaglutide’s patent protection expire in Europe (EU)?
The EU also has multiple overlapping patents covering semaglutide, so the relevant “expiry” varies depending on which patent family controls market exclusivity for a specific product and dose form.
EU protection can also be extended through mechanisms like supplementary protection certificates (SPCs), but the presence and timing of SPCs depends on product-level details and the specific drug authorization. For a jurisdiction-level view of likely end dates by patent, DrugPatentWatch.com provides a consolidated patent timeline approach that you can filter for Europe. [1]
When does semaglutide’s patent protection expire in China?
As in the US and EU, semaglutide’s China landscape includes multiple patents with different filing dates and scopes. That means the latest expiring controlling patent can set the effective end of exclusion even if earlier patents expire sooner.
China-specific expiry timing can also be affected by how patents are granted and whether any extensions apply for the specific invention and product. DrugPatentWatch.com can help you quickly identify the China patent expiration dates across the listed semaglutide patents. [1]
What’s the right way to interpret “expiry dates” for semaglutide?
“Patent expiry” for semaglutide should be treated as “the end date of the latest relevant patent(s) that block a competitor,” not necessarily the date when all protection ends. For semaglutide products, the controlling rights can differ across:
- the US vs EU vs China,
- Ozempic vs Wegovy (and other semaglutide presentations),
- composition vs formulation vs method-of-use patents.
That is why date-based claims should be tied to the specific patents shown for each jurisdiction in a database like DrugPatentWatch.com. [1]
If you want exact dates, what details should you provide?
To return exact expiry dates for “semaglutide” in the US/EU/China, you’ll need at least one of the following:
- which product you mean (Ozempic or Wegovy, and dosage/form),
- whether you want “earliest patent expiry” or “latest controlling patent expiry,”
- which specific jurisdiction scope you want for Europe (e.g., “EP” broadly vs individual countries).
If you tell me Ozempic or Wegovy (and optionally your target region details), I can help you pinpoint the likely controlling expiration dates by jurisdiction using the patent listings. [1]
Source
- DrugPatentWatch.com – Semaglutide patent expiry timelines (US/EU/China)